CURATIS N AG (CURN) - Total Assets
Based on the latest financial reports, CURATIS N AG (CURN) holds total assets worth CHF54.52 Million CHF (≈ $68.93 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CURATIS N AG (CURN) net assets for net asset value and shareholders' equity analysis.
CURATIS N AG - Total Assets Trend (2002–2024)
This chart illustrates how CURATIS N AG's total assets have evolved over time, based on quarterly financial data.
CURATIS N AG - Asset Composition Analysis
Current Asset Composition (December 2024)
CURATIS N AG's total assets of CHF54.52 Million consist of 10.6% current assets and 89.4% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF3.01 Million | 5.4% |
| Accounts Receivable | CHF1.56 Million | 2.8% |
| Inventory | CHF1.32 Million | 2.4% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF49.38 Million | 88.9% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how CURATIS N AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CURATIS N AG market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CURATIS N AG's current assets represent 10.6% of total assets in 2024, a decrease from 36.2% in 2002.
- Cash Position: Cash and equivalents constituted 5.4% of total assets in 2024, down from 6.5% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 88.0% of total assets, an increase from 3.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 88.9% of total assets.
CURATIS N AG Competitors by Total Assets
Key competitors of CURATIS N AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
CURATIS N AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.50 | 0.92 | 1.09 |
| Quick Ratio | 1.07 | 0.72 | 1.09 |
| Cash Ratio | 0.62 | 0.51 | 0.00 |
| Working Capital | CHF1.65 Million | CHF-555.00K | CHF17.00K |
CURATIS N AG - Advanced Valuation Insights
This section examines the relationship between CURATIS N AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.06 |
| Latest Market Cap to Assets Ratio | 1.61 |
| Asset Growth Rate (YoY) | 46180.0% |
| Total Assets | CHF55.54 Million |
| Market Capitalization | $89.64 Million USD |
Valuation Analysis
Above Book Valuation: The market values CURATIS N AG's assets above their book value (1.61x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: CURATIS N AG's assets grew by 46180.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CURATIS N AG (2002–2024)
The table below shows the annual total assets of CURATIS N AG from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF55.54 Million ≈ $70.21 Million |
+46180.00% |
| 2023-12-31 | CHF120.00K ≈ $151.71K |
-99.15% |
| 2022-12-31 | CHF14.05 Million ≈ $17.76 Million |
+10227.94% |
| 2021-12-31 | CHF136.00K ≈ $171.94K |
+7.09% |
| 2020-12-31 | CHF127.00K ≈ $160.56K |
-94.16% |
| 2019-12-31 | CHF2.17 Million ≈ $2.75 Million |
-0.73% |
| 2018-12-31 | CHF2.19 Million ≈ $2.77 Million |
-67.24% |
| 2017-12-31 | CHF6.68 Million ≈ $8.45 Million |
-5.70% |
| 2016-12-31 | CHF7.09 Million ≈ $8.96 Million |
-11.01% |
| 2015-12-31 | CHF7.97 Million ≈ $10.07 Million |
-19.95% |
| 2014-12-31 | CHF9.95 Million ≈ $12.58 Million |
-14.75% |
| 2013-12-31 | CHF11.67 Million ≈ $14.76 Million |
-39.27% |
| 2012-12-31 | CHF19.22 Million ≈ $24.30 Million |
+56.62% |
| 2011-12-31 | CHF12.27 Million ≈ $15.52 Million |
-8.15% |
| 2010-12-31 | CHF13.36 Million ≈ $16.89 Million |
+61.52% |
| 2009-12-31 | CHF8.27 Million ≈ $10.46 Million |
+62.45% |
| 2008-12-31 | CHF5.09 Million ≈ $6.44 Million |
-45.61% |
| 2007-12-31 | CHF9.36 Million ≈ $11.84 Million |
-32.69% |
| 2006-12-31 | CHF13.91 Million ≈ $17.58 Million |
-59.87% |
| 2005-12-31 | CHF34.66 Million ≈ $43.82 Million |
-41.97% |
| 2004-12-31 | CHF59.73 Million ≈ $75.51 Million |
-16.27% |
| 2003-12-31 | CHF71.33 Million ≈ $90.18 Million |
+3.32% |
| 2002-12-31 | CHF69.04 Million ≈ $87.29 Million |
-- |
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more